MwanzoNVAX • NASDAQ
add
Novavax Inc
$ 8.67
Baada ya Saa za Kazi:(1.85%)-0.16
$ 8.51
Imefungwa: 13 Jan, 17:35:54 GMT -5 · USD · NASDAQ · Kanusho
Bei iliyotangulia
$ 7.75
Bei za siku
$ 7.84 - $ 8.81
Bei za mwaka
$ 5.01 - $ 10.64
Thamani ya kampuni katika soko
1.41B USD
Wastani wa hisa zilizouzwa
3.21M
Uwiano wa bei na mapato
4.82
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Sep 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 70.44M | -16.64% |
Matumizi ya uendeshaji wa biashara | 46.12M | -42.92% |
Mapato halisi | -202.38M | -66.84% |
Kiwango cha faida halisi | -287.29 | -100.16% |
Mapato kwa kila hisa | -1.25 | -64.47% |
EBITDA | -72.80M | 37.84% |
Asilimia ya kodi ya mapato | 0.32% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Sep 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 762.89M | -16.12% |
Jumla ya mali | 1.18B | -31.10% |
Jumla ya dhima | 1.34B | -40.30% |
Jumla ya hisa | -156.67M | — |
hisa zilizosalia | 162.50M | — |
Uwiano wa bei na thamani | -8.07 | — |
Faida inayotokana na mali | -15.77% | — |
Faida inayotokana mtaji | -110.07% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Sep 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -202.38M | -66.84% |
Pesa kutokana na shughuli | 107.80M | 174.44% |
Pesa kutokana na uwekezaji | -136.53M | -527.83% |
Pesa kutokana na ufadhili | 42.44M | 43,854.64% |
Mabadiliko halisi ya pesa taslimu | 14.38M | 113.44% |
Mtiririko huru wa pesa | 96.84M | 223.39% |
Kuhusu
Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company's developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company is also developing vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria.
Novavax also develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
1987
Makao Makuu
Tovuti
Wafanyakazi
952
